171 related articles for article (PubMed ID: 31011901)
1. ASO Author Reflections: Prognostic Role of Pathologic Complete Response After Neoadjuvant Therapy in Digestive Cancer.
Wan T; Zhou YM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):587. PubMed ID: 31011901
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: The Prognostic Value of Pathologic Complete Response After Neoadjuvant Chemotherapy in Gastric Cancer.
Lin C; Liu F
Ann Surg Oncol; 2023 Sep; 30(9):5543. PubMed ID: 37355520
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Role of Genomic Assay to Predict Neoadjuvant Chemotherapy Response in Breast Cancer.
Pease AM; James TA
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):573-574. PubMed ID: 30783852
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Elimination of Breast Cancer Surgery in Complete Responders After Neoadjuvant Chemotherapy: Imaging Perspective.
Rauch GM
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):628-629. PubMed ID: 30244417
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy.
Hilal T; Patel BK
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):652-653. PubMed ID: 30324476
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Multimodal Treatment of Upper Gastrointestinal Signet Ring Cell Containing Cancer-Better Together.
Heger U; Schmidt T
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):761-762. PubMed ID: 30390168
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Moving Forward De-escalation of Axillary Surgery After Neoadjuvant Treatment in Breast Cancer.
Rubio IT
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):638-639. PubMed ID: 30284130
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Bilateral Mastectomy After Neoadjuvant Therapy: An Ever-Increasing Trend?
Kantor O; Yao K
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):650-651. PubMed ID: 30327968
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer.
Andrianello S; Marchegiani G; Salvia R
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):810-811. PubMed ID: 30374921
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Transoral Robotic Surgery Combined with Neoadjuvant Chemotherapy for Management of Advanced Laryngohypopharyngeal Cancer.
Park YM; Kim SH
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):894-895. PubMed ID: 30288650
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy.
Kim WH; Kim HJ
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):644-645. PubMed ID: 30315382
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: Rate of Axillary Lymph Node Dissection has Decreased in Patients Treated with Neoadjuvant Systemic Therapy.
Nguyen TT; Boughey JC
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):693-694. PubMed ID: 30421050
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients.
Newhook TE; Tzeng CD
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):749-750. PubMed ID: 31559543
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time-Highest Rates of Use Now in Triple-Negative and HER2+ Disease.
Murphy BL; Boughey JC
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):695-696. PubMed ID: 30465221
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Identifying pCR After Neoadjuvant Chemotherapy: The Key to Treatment De-escalation in Breast Cancer.
Lim DW; Hong NJL
Ann Surg Oncol; 2022 Dec; 29(Suppl 3):570-571. PubMed ID: 34435298
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated with Liver Recurrence.
Kubo H; Ohgi K; Sugiura T; Ashida R; Yamada M; Otsuka S; Yamazaki K; Todaka A; Sasaki K; Uesaka K
Ann Surg Oncol; 2022 Aug; 29(8):5003-5004. PubMed ID: 35381935
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: Predicting High-Risk Oncotype DX Recurrence Scores as a Strategy for Assessing Neoadjuvant Chemotherapy Eligibility.
Newman L
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):683-684. PubMed ID: 30377915
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: Improving Patient Selection for Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
Kantor O; James TA
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):640-641. PubMed ID: 30302645
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Is It Worth the Risk? The Benefit of Neoadjuvant Chemotherapy in Elderly Patients with Breast Cancer.
Williams AD; Barrio AV
Ann Surg Oncol; 2022 Dec; 29(13):8012-8013. PubMed ID: 35941345
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Reducing Axillary Lymph Node Dissections in Node-Positive Breast Cancer Patients.
van der Noordaa MEM; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):677-678. PubMed ID: 30474766
[No Abstract] [Full Text] [Related]
[Next] [New Search]
